Charles River Laboratories Intl

Saturday, 13 Jan, 2018

The company reported $1.18 earnings per share for the quarter, topping analysts' consensus estimates of $1.13 by $0.05. Charles River Laboratories Int now has $5.20 billion valuation. In the last 90 days, insiders have purchased 10,500 shares of company stock valued at $2,885 and have sold 1,056,776 shares valued at $2,011,952. About 145,216 shares traded. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. (NYSE:CRL) has risen 7.06% since January 11, 2017 and is uptrending. It has underperformed by 9.64% the S&P500.The move comes after 9 months negative chart setup for the $5.13 billion company.

Brandywine Global Investment Management Llc increased its stake in Gentex Corp (GNTX) by 1.37% based on its latest 2017Q3 regulatory filing with the SEC. The firm had revenue of $464.23 million during the quarter, compared to analyst estimates of $458.93 million.

Wasatch Advisors Inc, which manages about $19.28 billion and $7.37 billion US Long portfolio, decreased its stake in Penske Automotive Group Inc. The stock decreased 5.34% or $0.07 during the last trading session, reaching $1.24. About 181,715 shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 41.70% since January 11, 2017 and is downtrending. It has underperformed by 58.40% the S&P500.

Investors sentiment increased to 1.46 in Q3 2017. Its down 0.42, from 1.34 in 2017Q2. The stock was sold at an average price of $110.00, for a total value of $678,150.00.

A number of other hedge funds have also added to or reduced their stakes in the stock.

Charles River Laboratories International, Inc. has a 1-year low of $65.70 and a 1-year high of $89.18. Bridgewater Assocs LP owns 2,574 shares. (NYSE:CRL). Gemmer Asset Mgmt Llc has 156 shares for 0.01% of their portfolio. 372,800 shares of the company's stock were exchanged, compared to its average volume of 309,662. Cornerstone Capital Mngmt Hldgs Limited Co owns 125,967 shares. State Of Wisconsin Investment Board has 0% invested in Charles River Laboratories International, Inc. (NYSE:CRL). Monarch Ptnrs Asset Limited Liability Corp has invested 0.56% in Charles River Laboratories International, Inc. Charles River Laboratories Intl. earned a media sentiment score of 0.08 on Accern's scale. (NYSE:CRL). State Teachers Retirement Sys holds 98,584 shares. Oakbrook Invs Limited Co, a Illinois-based fund reported 4,517 shares.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide. (NYSE:CRL) or 14,015 shares. (NYSE:CRL). Rhumbline Advisers stated it has 0.02% in Charles River Laboratories International, Inc. (NYSE:CRL). 76,915 were reported by Kennedy Cap Mgmt Incorporated. 4,800 are held by Leavell Investment. (NYSE:CRL) for 319,780 shares. $171,228 worth of stock was sold by Smith David Ross on Monday, August 14. Credit Suisse Group restated a "neutral" rating and issued a $112.00 target price (up previously from $95.00) on shares of Charles River Laboratories Intl.in a research report on Monday, October 16th. Imperial Capital maintained Quanex Building Products Corporation (NYSE:NX) on Tuesday, January 5 with "Outperform" rating. Advisor Group Inc. now owns 1,538 shares of the medical research company's stock valued at $165,000 after purchasing an additional 945 shares during the last quarter. Shares for $9.78 million were sold by AHRENDTS ANGELA J on Tuesday, October 3. Therefore 77% are positive. The firm has "Buy" rating given on Thursday, June 29 by Jefferies. (NYSE:CRL) on Friday, January 8 with "Outperform" rating.

Among 52 analysts covering Apple Inc. As per Monday, October 12, the company rating was upgraded by Wells Fargo. The company was maintained on Monday, November 13 by Robert W. Baird.

COPYRIGHT VIOLATION WARNING: "Charles River Laboratories Intl". Argus started coverage on shares of Charles River Laboratories Intl.in a research note on Wednesday, December 13th.

In related news, insider Bradley Nixon Scharfe sold 1,000,000 shares of Charles River Laboratories Intl. stock in a transaction dated Friday, November 10th.

Mai Wealth Advisors decreased Netflix Inc. The company's institutional ownership is monitored at 0 percent. It also reduced its holding in Moodys Corp Com (NYSE:MCO) by 4,833 shares in the quarter, leaving it with 329,106 shares, and cut its stake in Mfc Ishares Tr Russell 2000 Va (IWN).

Janney Montgomery Scott Llc increased Pimco Intrm Mun Bd Etf (MUNI) stake by 6,537 shares to 12,969 valued at $698,000 in 2017Q3.

Healthinvest Partners Ab, which manages about $85.64M US Long portfolio, upped its stake in Mckesson Corp (NYSE:MCK) by 5,500 shares to 68,600 shares, valued at $10.54M in 2017Q3, according to the filing. Ishs Acwi Ex Us Etf (ACWX) was raised too. Nordea Investment Management AB increased its stake in Charles River Laboratories International by 20.7% in the third quarter. Therefore 71% are positive. Aqr Mgmt Limited Liability reported 0.19% in Charles River Laboratories International, Inc. The company was maintained on Friday, August 28 by William Blair. On Tuesday, September 12 the stock rating was maintained by Jefferies with "Hold". The rating was initiated by Sidoti on Tuesday, September 19 with "Hold". As per Friday, January 8, the company rating was maintained by Jefferies. As per Wednesday, November 16, the company rating was maintained by Maxim Group. The firm has "Hold" rating given on Wednesday, August 30 by Cantor Fitzgerald. (NYSE:CRL) on Monday, November 13 with "Buy" rating. (NASDAQ:AAPL), 40 have Buy rating, 1 Sell and 11 Hold. "Inc (NYSE:CRL) Forecasted to Earn Q1 2018 Earnings of $1.29 Per Share" was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. During the same quarter past year, the company earned $1.03 earnings per share. CRL's profit will be $59.67 million for 22.20 P/E if the $1.26 EPS becomes a reality.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.